Portfolio Companies

Our investments and value creation approach

Home > Portfolio
AUM
$ 0 M

$XYZ

AUM

Deployed across control investments

CONTROL
INVESTMENTS
0

Majority/full control stakes

GLOBAL
OPERATING SITES
0

Across regulated markets

REGULATED
MARKETS
0 +

U.S., Europe, Emerging

Flagship Investment - Acquired 2023

A U.S.-focused specialty pharmaceutical platform developing, sourcing and commercializing a broad portfolio of injectable medicines across anti-infectives, oncology and critical care, with an established presence in the U.S. hospital market.

Our Role

Control investment with Parami partners embedded in executive leadership and day-to-day operations. Parami has led Sagent’s stabilization and strategic repositioning—reshaping its portfolio, operating model, partnerships and growth agenda while taking direct responsibility for execution.

Value Creation Initiatives

  • Defined and executed a strategic roadmap to reposition Sagent as a focused, asset-light specialty injectables platform with a stronger portfolio, resilient supply network and sustainable growth model
  • Reshaped the business through the divestiture of non-core assets, selective strategic investments and disciplined portfolio prioritization
  • Acquired a complementary injectable portfolio to strengthen the commercial offering and development pipeline
  • Established strategic product-development and supply partnerships with leading global pharmaceutical companies
  • Stabilized and diversified the CMO, API and component supply network
  • Strengthened regulatory, quality, financial, technology and governance capabilities
  • Built a more focused commercial and business-development engine to drive sustainable growth

Segment: Specialty Injectables  |  Market: United States  |  Type: Control Investment

Platform Investment — Acquired April 2024

Built on the legacy of Shantha Biotechnics, one of India’s pioneering vaccine companies, Shantha is an integrated vaccines, biologics and sterile injectables platform. Its capabilities span R&D, product development, technology transfer, scale-up and commercial manufacturing across two specialized campuses, serving regulated and global health markets.

Our Role

Control investment with Parami partners embedded in executive leadership and day-to-day operations. Parami has led the restart of vaccine manufacturing, re-established commercial supply, rebuilt the R&D and product-development pipeline—including the Hexavalent vaccine program—and commercialized the injectables platform through partnerships with global pharmaceutical companies.

Value Creation Initiatives

  • Defined and executed a phased strategy to rebuild Shantha as an integrated vaccines, biologics and sterile injectables platform—restarting commercial production, rebuilding R&D and activating installed capacity through global partnerships
  • Restored oral cholera vaccine production and commercial supply, securing Indian marketing authorization, WHO prequalification and a UNICEF supply award
  • Rebuilt vaccine R&D and product-development capabilities, advancing the Hexavalent vaccine and other combination and standalone vaccine programs
  • Validated the sterile injectables platform through an anchor contract with a leading global pharmaceutical company
  • Expanded the opportunity pipeline across insulin, GLP-1 and other biologic programs
  • Re-established two complementary manufacturing campuses with significant vaccine and sterile injectables capacity
  • Rebuilt a 600-plus-person organization with deep expertise in biologics manufacturing, quality and regulatory operations
  • Created pathways to regulated, global health and biopharmaceutical CDMO markets

Segment: Vaccines, Biologics & Sterile Injectables |  Market: Global  |  Type: Control Platform Investment

Early-Stage Investment

TransCath is an Indian medical-device company developing and manufacturing high-quality catheter products for domestic and international markets. The company was established to challenge the belief that globally competitive medical devices cannot be designed and manufactured in India at scale.

Our Role

Parami has remained a long-term strategic investor in TransCath, supporting its evolution from an entrepreneurial venture into a scalable medical-device manufacturing platform. Our involvement has focused on strategic direction, capability building, organizational development and the company’s path towards global markets.

Value Creation Initiatives

  • Defined the strategic roadmap to build a globally competitive catheter-development and manufacturing platform from India
  • Supported the development of indigenous product-design and manufacturing capabilities
  • Invested in manufacturing infrastructure, quality systems and organizational capabilities required for scale
  • Strengthened the platform’s focus on product quality, cost competitiveness and manufacturing efficiency
  • Supported the development of local technical expertise and a collaborative medical-device ecosystem
  • Created a pathway for expansion into international markets and long-term global partnerships

Segment: Medical Devices   |  Market: India & Global |  Type: Early-Stage Growth Investment